Updated national and international hypertension guidelines: A review of current recommendations

Drugs

Volumn 74, Issue 17, 2014, Pages 2033-2051

  Kjeldsen, Sverre ^a   Feldman, Ross D ^b   Lisheng, Liu ^c   Mourad, Jean Jacques ^d   Chiang, Chern En ^e   Zhang, Weizhong ^f   Wu, Zhaosu ^g   Li, Wei ^c   Williams, Bryan ^h  

^a UNIVERSITY OF OSLO   (Norway)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c FUWAI HOSPITAL   (China)

^d AVICENNE HOSPITAL   (France)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

^f SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^g CAPITAL MEDICAL UNIVERSITY   (China)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYPERTENSIVE AGENT;

ALGORITHM; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); CONSENSUS; DIABETES MELLITUS; EDUCATION PROGRAM; HEALTH BEHAVIOR; HEALTH PROGRAM; HUMAN; HYPERTENSION; MEDICAL PRACTICE; MEDICAL SOCIETY; PILL; PRACTICE GUIDELINE; REVIEW; INTERNATIONAL COOPERATION; STANDARDS;

HUMANS; HYPERTENSION; INTERNATIONALITY; PRACTICE GUIDELINES AS TOPIC;

EID: 84919903956     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-014-0306-5     Document Type: Review

References (54)

1. World Health Organisation. A global brief on hypertension: silent killer, global public health crisis. 2013. http://apps.who.int/iris/bitstream/10665/79059/1/WHO-DCO-WHD-2013.2-eng.pdf?ua=1. Accessed 19 June 2014.
2. He FJ, MacGregor GA. Cost of poor blood pressure control in the UK: 62000 unnecessary deaths per year. J Hum Hypertens. 2003;17:455-7.
3. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint national committee (JNC 8). JAMA. 2014;311:507-20.
4. Go AS, Bauman M, King SMC, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. Hypertension. 2014;63:878-85.
5. Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens. 2014;32:3-15.
6. Dasgupta K, Quinn RR, Zarnke KB, et al. The 2014 Canadian Hypertension Education Program (CHEP) recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention and treatment of hypertension. Can J Cardiol. 2014;30:485-501.
7. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159-219.
8. National Institute for Health and Care Excellence. Hypertension: clinical management of primary hypertension in adults (Clinical guideline 127). http://guidance.nice.org.uk/CG127. Accessed 19 June 2014.
9. Blacher J, Halimi JM, Hanon O, et al. Management of hypertension in adults: the 2013 French Society of Hypertension guidelines. Fundam Clin Pharmacol. 2014;28:1-9.
10. Chiang C-E, Wang T-D, Li Y-H, et al. 2010 Guidelines of the Taiwan Society of Cardiology for the management of hypertension. J Formos Med Assoc. 2010;109:740-73.
11. Liu LS. 2010 Chinese guidelines for the management of hypertension. Zhonghua Xin Xue Guan Bing Za Zhi. 2011;39:579-615.
12. Lovibond K, Jowett S, Barton P, et al. Cost-effectiveness of options for the diagnosis of high blood pressure in primary care: a modelling study. Lancet. 2011;378:1219-30.
13. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887-98.
14. Wright JT Jr, Fine LJ, Lackland DT, et al. Evidence supporting a systolic blood pressure goal of less than 150 mmHg in patients aged 60 years or older: the minority view. Ann Intern Med. 2014;160:499-503.
15. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28:1462-536.
16. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206-52.
17. ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575-85.
18. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet. 1998;351:1755-62.
19. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-13.
20. Bangalore S, Kumar S, Lobach I, et al. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and Bayesian random-effects meta-analyses of randomized trials. Circulation. 2011;123:2799-810.
21. Cooper-DeHoff RM, Gong Y, Handberg EM, et al. TIght blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010;304:61-8.
22. Reboldi G, Gentile G, Angeli F, et al. Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73,913 patients. J Hypertens. 2011;29:1253-69.
23. Arguedas JA, Perez MI, Wright JM. Treatment blood pressure targets for hypertension. Cochrane Database Syst Rev. 2009:CD004349.
24. Upadhyay A, Earley A, Haynes SM, et al. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med. 2011;154:541-8.
25. Appel LJ, Wright JT, Greene T, et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med. 2010;363:918-29.
26. Eckel RH, Jakicic JM, Ard JD, et al. AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation. 2014;129:25(Suppl. 2):S76-99.
27. Simplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57:911-7.
28. Institute of Medicine. Sodium intake in populations. Assessment of evidence. 2013. http://www.iom.edu/Reports/2013/Sodium-Intake-in-Populations-Assessment-of-Evidence.aspx. Accessed 5 Sept 2014.
29. Graudal N, Jürgens G, Baslund B, et al. Compared with usual sodium intake, low- and excessive-sodium diets are associated with increased mortality: a meta-analysis. Am J Hypertens. 2014;27:1129-37.
30. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ. 1992;304:405-12.
31. Wiysonge CS, Bradley HA, Volmink J, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2012:CD002003.
32. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292:2227-36.
33. Manrique C, Giles TD, Ferdinand KC, et al. Realities of newer β-blockers for the management of hypertension. J Clin Hypertens. 2009;11:369-75.
34. Bonet S, Agustí A, Arnau JM, et al. Β-adrenergic blocking agents in heart failure: benefits of vasodilating and nonvasodilating agents according to patients' characteristics: a meta-analysis of clinical trials. Arch Intern Med. 2000;160:621-7.
35. Feldman RD, Zou GY, Vandervoort MK, et al. A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension. 2009;53:646-53.
36. Jaffe MG, Lee GA, Young JD, et al. Improved blood pressure control associated with a large-scale hypertension program. JAMA. 2013;310:699-705.
37. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122:290-300.
38. Corrao G, Parodi A, Zambon A, et al. Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice. J Hypertens. 2010;28:1587-90.
39. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-59.
40. Parving H-H, Brenner BM, McMurray JJV, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367:2204-13.
41. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55:399-407.
42. Kjeldsen SE, Messerli FH, Chiang C-E, et al. Are fixed-dose combination antihypertensives suitable as first-line therapy? Curr Med Res Opin. 2012;28:1685-97.
43. Dickson M, Plauschinat CA. Racial differences in medication compliance and healthcare utilization among hypertensive medicaid recipients: fixed-dose vs free-combination treatment. Ethn Dis. 2008;18:204-9.
44. Dickson M, Plauschinat CA. Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy. Am J Cardiovasc Drugs. 2008;8:45-50.
45. The ALLHAT Officers. Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2002;288:2981-97.
46. Leenen FHH, Nwachuku CE, Black HR, et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2006;48:374-84.
47. National Institute of Clinical Excellance. Hypertension in pregnancy, guideline 107. 2010. http://www.nice.org.uk/guidance/CG107 Accessed 5 Sept 2014.
48. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;19:b1665.
49. Esler MD, Krum H, Schlaich M, et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the symplicity htn-2 randomized, controlled trial. Circulation. 2012;126:2976-82.
50. Symplicity HTN-2 Investigators, Esler MD, Krum H, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376:1903-9.
51. Shimamoto K, Ando K, Fukita T, et al. The Japanese society of hypertension guidelines for the management of hypertension (JSH 2014). Hypertens Res. 2014;37(4):253-387.
52. Knott C, Mindell J. Health Survey for England: 2011. 2011. http://www.hscic.gov.uk/catalogue/PUB09300/HSE2011-Ch3-Hypertension.pdf. Accessed 19 June 2014.
53. McAlister FA, Feldman RD, Wyard K, et al. The impact of the Canadian hypertension education programme in its first decade. Eur Heart J. 2009;30:1434-9.
54. Peterson ED, Gaziano J, Greenland P. Recommendations for treating hypertension: what are the right goals and purposes? JAMA. 2013;311:474-6.